Well, the PEACE-3 trial demonstrated that the combination of enzalutamide plus radium-223 compared to enzalutamide alone demonstrated a statistically significant benefit in overall survival. This has a ratio of 0.76 with a P below the significance prefix threshold. And the difference in survival was 5.6 months between arms with 38.2 months for the combination arm. So the significance of this is that the combination of two survival benefit agents independently may improve the survival for our patients...
Well, the PEACE-3 trial demonstrated that the combination of enzalutamide plus radium-223 compared to enzalutamide alone demonstrated a statistically significant benefit in overall survival. This has a ratio of 0.76 with a P below the significance prefix threshold. And the difference in survival was 5.6 months between arms with 38.2 months for the combination arm. So the significance of this is that the combination of two survival benefit agents independently may improve the survival for our patients. This also was associated with an improvement in radiological progression-free survival and with a moderate but I think very manageable toxicity profile. The combination slightly increased the grade 3 to 5 adverse events from 19% to 29%. And in overall, I think it could be a good chance for our patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
